Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 8 full-time employees. The company went IPO on 2019-10-03. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. The company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. The company also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.
Follow-Up Questions
¿Quién es el CEO de Aprea Therapeutics Inc?
Dr. Oren Gilad es el President de Aprea Therapeutics Inc, se unió a la empresa desde 2022.
¿Qué tal es el rendimiento del precio de la acción APRE?
El precio actual de APRE es de $1.36, ha decreased un 0.56% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Aprea Therapeutics Inc?
Aprea Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Aprea Therapeutics Inc?
La capitalización bursátil actual de Aprea Therapeutics Inc es $7.9M
¿Es Aprea Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Aprea Therapeutics Inc, incluyendo 3 fuerte compra, 4 compra, 1 mantener, 0 venta, y 3 fuerte venta
